Innovent Biologics announced it will showcase multiple clinical and preclinical results for its obesity and metabolic disease treatments, including mazdutide and next-generation drugs, at the 2026 American Diabetes Association Scientific Sessions. The presentations cover studies on adults and adolescents with obesity and type 2 diabetes, highlighting mazdutide's benefits in weight loss and glycemic control. Innovent also revealed data on new oral GLP-1 receptor agonists and other innovative therapies aimed at improving treatment tolerability and effectiveness. These developments position Innovent as a rising leader in obesity and metabolic disease treatment globally.
Mesoblast Limited has drawn $50 million from a new five-year loan facility provided by a shareholder, replacing higher-cost short-term debt. This move strengthens Mesoblast's balance sheet by lowering interest costs and removing short-term obligation...
HUTCHMED announced positive Phase II trial results for fanregratinib in treating advanced intrahepatic cholangiocarcinoma (ICC) with FGFR2 fusion/rearrangement. The study showed a 42.5% objective response rate and median overall survival of 16.6 mont...
Western Union and Intermex announced that regulatory approvals for Western Union's acquisition of Intermex have been received from 51 U.S. states and international jurisdictions, with only one U.S. state, New York, pending approval. Both companies ar...
Modern Therapy Group has introduced a virtual intensive outpatient program (IOP) designed for adults dealing with depression, anxiety, trauma, and other mental health issues. This program offers structured, clinician-led treatment five days a week vi...
Meyer Wilson Werning, an investor protection law firm, is investigating UBS advisor Daniel Merithew Allen for allegedly recommending unapproved investments in 99 Acquisition Group LLC to clients. This practice, known as "selling away," violates FINRA...
